Search 

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary messenger RNAi GOLD™ Platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others

Sygnature Discovery - enabling success in drug discovery

Sygnature Discovery (www.sygnaturediscovery.com ) is a leading independent provider of integrated drug discovery resource and expertise.  Since 2011, 33 compounds discovered by Sygnature for clients have entered pre-clinical development and so far 17 of these have progressed to clinical trials (Phases I, II and III).

We add considerable value to our clients'​ research projects by providing intellectual input and drug discovery expertise to accelerate target validation, hit identification, hit-to-lead, lead optimisation and drug discovery programmes.  Sygnature's capabilities include medicinal chemistry, in vitro biology, computational chemistry and informatics, DMPK, and protein crystallography (via affiliate company Peak Proteins).  We can also provide pre-clinical experimental services support through our sister company RenaSci.

Sygnature Discovery operates a business whose primary focus is value creation for our clients, through the application of integrated drug discovery know-how and close working relationships.  We have built a team of over 400 staff including pharmaceutical industry-experienced research scientists (over 80% PhD qualified) with the ability to collaborate on an equal footing with our clients’ scientists to drive drug discovery projects towards the clinic.

In summary, Sygnature Discovery offers:

•    Target validation
•    Hit identification
•    Hit-to-lead
•    Lead optimisation
•    Integrated drug discovery programmes
•    Medicinal chemistry
•    In vitro biology (including biophysics and live cell imaging)
•    Computational chemistry
•    DMPK
•    Protein crystallography

SYNthesis is a chemistry-focussed, contract research organisation providing custom synthesis and medicinal chemistry services.
The company was established in 2007 and operates a unique, hybrid business model combining medicinal chemistry & project management expertise based in both Australia and the USA, with high quality synthetic chemistry based in China.
In addition to Melbourne (Australia) where SYNthesis med chem's global headquarters are located, the company also has operations in Shanghai & Suzhou (China) together with offices in the UK and USA.
SYNthesis currently employs over 250 chemists based in Australia, China & the USA.
Our medicinal chemists provide the design, innovation, creativity and problem solving expertise required to complement the skills & capabilities of the company's expert team of synthetic chemists based in China.
Our medicinal chemists are all experienced and highly skilled scientists with a track record of delivering clinical candidates, a passion for discovering new medicines and a comprehensive insight gained from managing more than 100 projects covering all phases of the pharmaceutical R&D process.
They also act as project managers for custom synthesis and medicinal chemistry projects.

Vaccitech is a clinical stage T cell immunotherapy company developing products to treat and prevent cancer and infectious diseases. The company’s proprietary technology platform, comprising

Chimpanzee Adenovirus (prime) and MVA (boost) is exceptional at inducing, boosting and maintaining CD8+ and CD4+ T cells, as well as antibodies. The Vaccitech prime-boost platform is licensed from one of the most prestigious vaccine research institutes in the world, the Jenner Institute at the University of Oxford. Vaccitech currently has a Phase 2 clinical program for prostate cancer, a Phase 1 clinical program for chronic HBV and is poised to enter the clinic with HPV and NSCLC therapeutics. The company is also co-developing products for MERS coronavirus and Herpes Zoster with international collaborators and has outlicensed its rights to the ChAdOx COVID-19 vaccine being developed by the University of Oxford to AstraZeneca. Vaccitech is backed by leading institutions including M&G, GV, Gilead Sciences, Sequoia Capital China, Korea Investment Partners and Oxford Sciences Innovation.

At Veratrak we are transforming the way the pharmaceutical supply chain works together to deliver high quality and cost effective health care.

Veratrak is a document and workflow management platform that allows pharmaceutical supply chain companies to communicate and work together with their customers and suppliers with greater efficiency, security, and auditability.